Full Press Release Details
ABVC BioPharma Regains Nasdaq Minimum Bid Price
Silicon Valley, CA - May 14, 2025 -
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company
developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced
that it has received official notice from the Nasdaq Listing Qualifications Department confirming that the Company has regained compliance
with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
According to Nasdaq's notification dated
May 13, 2025, ABVC's common stock successfully maintained a closing bid price at or above $1.00 for 10 consecutive trading days
from April 29, 2025 to May 12, 2025, satisfying the exchange's compliance standard for the referenced rule. This development formally
closes this deficiency matter.
"This is more than a compliance milestone
- it is a clear validation of our turnaround strategy and unwavering commitment to shareholder value," said Dr. Uttam Patil,
ABVC Chief Executive Officer.
Compairing fiscal year 2024 to 2023, ABVC has
made significant strides:
The reinstatement of Nasdaq compliance follows
a period of focused restructuring, paving the way for future success. ABVC is currently in preliminary discussions with leading pharmaceutical
and AI companies to co-develop its Phase III-ready candidates for Major Depressive Disorder (MDD) and ADHD, both multibillion-dollar global
"We see this as a critical inflection point,"
said Dr. Patil. "ABVC is no longer just a clinical-stage biotech - we are building a platform for global commercialization,
powered by science, supported by strategy, and our continued Nasdaq listing demonstrates our ability to meet high listing standards."
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus ) under development. For its drug
products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University
of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus , the Company intends to conduct pivotal clinical trials
(Phase III) through global partnerships.
Forward-Looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based
on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control,
and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size
and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval
to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are
urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer
to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United
States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of
the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such state or jurisdiction.
Email: uttam@ambrivis.com